Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies

查看全文 作　　者：[1]ShuguangTan;Danqing [1]Chen;Kefang [2,3]Liu;Mengnan [1,4]He;Hao [5]Song;Yi [1,4]Shi;Jun [2,3]Liu;Catherine W.-H. [6]Zhang;Jianxun [1]Qi;Jinghua [1,4,7]Yan;Shan [8]Gao;George F. [1,2,5,9]Gao

机构地区：[1]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;[2]National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China;[3]College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China;[4]College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China;[5]Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China;[6]ImmuFucell Biotechnology Co.Ltd., Beijing 100102, China;[7]CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;[8]CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, Jiangsu 215163, China;[9]Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China

出　　处：《Protein & Cell》索引2016年第7卷第12期,共12页

基　　金：This work was supported by the National Basic Research Program (973 Program) (Nos. 2013CB531502 and 2014CB542503), the National Natural Science Foundation of China (Grant Nos. 31390432 and 31500722), Grand S&T project of China Health and Family Planning Commission (2013ZX10004608-002 and 2016ZX10004201-009), the Strategic Priority Research Program of the Chinese Academy of Sciences (CAS; XDB08020100). GFG is supported partly as a leading principal investigator of the NSFC Innovative Research Group (81321063). 摘　　要：基于抗体的 PD-1/PD-L1 封锁治疗为癌症在免疫疗法拿了中心舞台,与多重临床的成功。发信号的 PD-1 在肿瘤驱动的 T 房间机能障碍起枢轴的作用。与优先的途径相对照产生或增加肿瘤特定的 T 房间回答,基于抗体的 PD-1/PD-L1 封锁指向导致肿瘤的 T 房间缺点并且恢复先存在调制 antitumor 免疫的 T 房间功能。在这评论,表达式规定和 PD-1 的禁止的函数和基于抗体的 PD-1/PD-L1 封锁治疗的现在的理解上的基本知识简短被总结。我们然后有关 PD-1/PD-Ls 相互作用的结构的基础集中于最近的突破工作并且怎么指向 PD-L1 的治疗学的抗体, pembrolizumab 指向 PD-1 和 avelumab,与 PD-1/PD-L1 的绑定竞争打断 PD-1/PD-L1 相互作用。我们相信这个结构的信息将有益于指向 PD-1 发信号的治疗学的抗体的设计和改进。 关键词：PD-1/PD-L1 相互作用检查点封锁分子的基础治疗学的抗体

相关文献

参考文献（90）
引证文献（8）
耦合文献（10）

参考文献(90)

引证文献(8)

耦合文献(10)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies

参考文献(90)

引证文献(8)

耦合文献(10)

用户提示